Broker tips: Barclays, Glaxosmithkline, Antofagasta...

The stock market gave a warm reaction to Barclays' first-half results on Wednesday, with analysts upbeat about the bank's better-than-expected results.Numis Securities reiterated a 'buy' recommendation for the stock, saying that "Investment Bank revenues were better than feared, the balance sheet is strengthening and the non-core run-off is progressing well".Espirito Santo, Deutsche Bank and Santander also kept their 'buy' ratings for Barclays.Liberum Capital has lowered its recommendation for pharmaceutical group Glaxosmithkline (GSK) from 'hold' to 'sell', saying it sees an uncertain outlook for the business. The broker has slashed its target price for the stock from 1,500p to 1,350p."Our analysis shows the immense pressure the business is under is likely to lead to underinvestment in core areas," Liberum explained.A broadly in-line production update from Antofagasta underwhelmed investors on Wednesday with Westhouse Securities dampening sentiment by downgrading the stock from 'add' to 'neutral'.Westhouse said it has lowered its rating in response to the recent share-price movement - the stock had risen 12% over the last month as of Tuesday - with Antofagasta starting to look "fully valued" against others in the sector.BC